The short answer: the GLP-1 and obesity market in 2026 has shifted from an efficacy race to an access race. The top of the efficacy range is now near 28 percent weight loss with the triple agonist retatrutide, which is bariatric surgery territory, and the field has begun asking whether every patient even wants that. Meanwhile the real constraint, access, moved fast: two oral products launched, list prices collapsed, and Medicare began covering these drugs in July 2026.
Here is the full map of what is approved, what is coming, and what each company is actually betting on.
What is approved
Novo Nordisk and Eli Lilly hold almost the entire market. The approved products include:
- Zepbound and Mounjaro (tirzepatide, Eli Lilly), a GLP-1 and GIP dual agonist, around 21 percent weight loss.
- Wegovy and Ozempic (semaglutide, Novo Nordisk), a GLP-1 agonist, around 15 percent.
- Oral semaglutide (Novo Nordisk), the pill version, which launched in the United States in early 2026.
- Orforglipron (Eli Lilly), an oral non peptide GLP-1 agonist, around 11 to 12 percent, approved in April 2026.
The efficacy staircase
The simplest way to read the field is as a staircase, where each additional receptor recruited lifts the ceiling:
- Single receptor, GLP-1 alone: around 15 percent.
- Dual receptor, GLP-1 plus GIP: around 21 percent.
- Triple receptor, adding glucagon (retatrutide): 28.3 percent at 80 weeks, the highest reported in a late stage trial.
- Amylin combination (CagriSema): 22.7 percent, a different pathway rather than a bigger dose.
The five bets each company is making
This is not one race. It is five, and at least three could be right at once.
- The triple agonist bet (Eli Lilly, retatrutide). If more receptors lift efficacy, recruit three. It worked, with the highest weight loss yet reported.
- The amylin bet (Novo Nordisk, Roche, Zealand). Use a different hormone for comparable weight loss with better tolerability and adherence.
- The oral bet (Novo Nordisk, Eli Lilly). Access was always the constraint, not efficacy. A pill that reaches everyone beats an injection that reaches a fraction.
- The durability bet (Amgen, Pfizer). Monthly dosing, with weight loss that persists after stopping, solves a different problem than a bigger number.
- The beyond weight bet (Boehringer, Roche, and effectively everyone). The real value is what the weight loss does to the liver, heart, kidneys, and joints, because those indications unlock reimbursement.
How the economics changed
- List prices collapsed from around $1,000 a month to a fraction of that after pricing agreements.
- Medicare began covering these drugs in July 2026 under a bridge program, with eligible beneficiaries paying $50 a month.
- Both oral products are priced from $149 a month for self pay, a customer acquisition decision rather than a pricing one.
- Two of the largest pharmaceutical companies in the world are now routing around the pharmacy benefit manager with direct distribution.
Frequently asked questions
What is the most effective weight loss drug in 2026?
By reported trial data, the triple agonist retatrutide has shown the highest weight loss, around 28 percent at 80 weeks, though it is not yet approved. Among approved products, tirzepatide leads at around 21 percent.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a single GLP-1 receptor agonist, showing around 15 percent weight loss. Tirzepatide is a dual GLP-1 and GIP agonist, showing around 21 percent. Adding the GIP receptor is what lifts the efficacy.
Does Medicare cover weight loss drugs?
As of July 2026, Medicare began covering certain GLP-1 drugs for obesity under a bridge program, with eligible Part D beneficiaries paying a reduced monthly copay. Coverage details and eligibility should be confirmed against current program terms.
Are there weight loss pills as effective as the injections?
The oral GLP-1 products launched in 2026 deliver meaningfully less weight loss than the leading injections, but they expand access dramatically. Their strategic value is reaching patients who would not take an injection, rather than matching peak efficacy.
Get the full market map
We built a complete map with the approved products, the efficacy staircase, the five bets explained in detail with the evidence and risks, the economics, and what all of it creates for companies that supply this market.
